Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity - PubMed

Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity

M E Ryan et al. Curr Med Chem. 2001 Feb.

Abstract

Diabetes mellitus in rats is characterized by excessive activity of several matrix metalloproteinases (MMPs), notably collagenase(s) and gelatinase(s), in skin, gingiva, and other tissues. A number of tetracyclines (TCs), both antimicrobial compounds as well as chemically modified non-antimicrobial TC analogues (CMTs) are known to possess potent inhibitory activity against these enzymes. Three conventional antimicrobial TCs and six CMTs were used in this study. In vitro, doxycycline was shown to possess higher inhibitory capacity (i.e. lower IC(max)) against diabetic rat skin collagenase than either minocycline or tetracycline HCl. Addition of excess zinc partially reversed the proteinase inhibition by TCs. In vivo, using rats made diabetic with streptozotocin (STZ), oral administration of various TCs led to decreased weight loss and substantial reductions in the activity of both skin collagenase and skin gelatinase (primarily MMP-9, 92 kDa) without affecting blood glucose. Using an in vitro spectrophotometric technique, the Zn(++) reactivity of several CMTs was assessed and found to be positively related to the potency of these compounds as MMP inhibitors. One particular CMT (CMT-5, pyrazole analogue), which is neither antimicrobial nor capable of binding metal cations, did not inhibit the MMPs. TCs have potential utility in management of diabetic complications mediated by excessive activity of MMPs.

Similar articles

• MMP-mediated events in diabetes.

  Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. Ryan ME, et al. Ann N Y Acad Sci. 1999 Jun 30;878:311-34. doi: 10.1111/j.1749-6632.1999.tb07692.x. Ann N Y Acad Sci. 1999. PMID: 10415738

• Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.

  Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub LM, Vernillo AT. Ramamurthy NS, et al. J Periodontol. 2002 Jul;73(7):726-34. doi: 10.1902/jop.2002.73.7.726. J Periodontol. 2002. PMID: 12146531

• Chemically-modified tetracycline normalizes collagen metabolism in diabetic rats: a dose-response study.

  Yu Z, Ramamurthy NS, Leung M, Chang KM, McNamara TF, Golub LM. Yu Z, et al. J Periodontal Res. 1993 Nov;28(6 Pt 1):420-8. J Periodontal Res. 1993. PMID: 8254459

• Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.

  Rifkin BR, Vernillo AT, Golub LM. Rifkin BR, et al. J Periodontol. 1993 Aug;64(8 Suppl):819-27. doi: 10.1902/jop.1993.64.8s.819. J Periodontol. 1993. PMID: 8410621 Review.

• Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.

  Gu Y, Lee HM, Simon SR, Golub LM. Gu Y, et al. Pharmacol Res. 2011 Dec;64(6):595-601. doi: 10.1016/j.phrs.2011.05.011. Epub 2011 May 31. Pharmacol Res. 2011. PMID: 21651982 Review.

Cited by

• Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes.

  Frankwich K, Tibble C, Torres-Gonzalez M, Bonner M, Lefkowitz R, Tyndall M, Schmid-Schönbein GW, Villarreal F, Heller M, Herbst K. Frankwich K, et al. J Inflamm (Lond). 2012 Oct 1;9(1):35. doi: 10.1186/1476-9255-9-35. J Inflamm (Lond). 2012. PMID: 23025537 Free PMC article.

• Role of nitric oxide in matrix remodeling in diabetes and heart failure.

  Tyagi SC, Hayden MR. Tyagi SC, et al. Heart Fail Rev. 2003 Jan;8(1):23-8. doi: 10.1023/a:1022138803293. Heart Fail Rev. 2003. PMID: 12652156 Review.

• The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia.

  Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y, Geyer O. Mathalone N, et al. Graefes Arch Clin Exp Ophthalmol. 2007 May;245(5):725-32. doi: 10.1007/s00417-006-0362-y. Epub 2006 Oct 6. Graefes Arch Clin Exp Ophthalmol. 2007. PMID: 17024442

• Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers.

  Elewa MA, Al-Gayyar MM, Schaalan MF, Abd El Galil KH, Ebrahim MA, El-Shishtawy MM. Elewa MA, et al. Clin Exp Metastasis. 2015 Jun;32(5):479-93. doi: 10.1007/s10585-015-9721-6. Epub 2015 May 22. Clin Exp Metastasis. 2015. PMID: 25999065

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Bentham Science Publishers Ltd.
  • Ingenta plc

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal